Physician profile
Lena Chang
NPI 1932120540
$6,825.28
in general payments reported to CMS, 2019-2025
22 companies · $1,472 in 2025
The $1,472 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,019 · 2020: $2,655 · 2021: $717 · 2022: $490 · 2023: $348 · 2024: $125 · 2025: $1,472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,257 · Travel and Lodging: $688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,256.72 |
| Travel and Lodging | $688.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ivantis, INC | $2,338.36 | 2020-2021 | |
| Carl Zeiss Meditec USA, INC. | $888.98 | 2025 | |
| Coopervision INC. | $568.99 | 2019-2023 | Myday Contact Lens, Misight Contact Lens |
| Glaukos Corporation | $447.70 | 2020-2025 | Idosetr, Istent Infinite |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $436.48 | 2019-2021 | |
| Allergan, INC. | $347.89 | 2019-2022 | |
| Johnson & Johnson Vision Care, INC. | $255.00 | 2019-2022 | |
| Visioneering Technologies, INC. | $195.70 | 2019 | |
| Alcon Vision LLC | $188.11 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $166.63 | 2022-2025 | Alden Scleral Zenlens |
| Oyster Point Pharma, INC. | $153.94 | 2023 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $143.16 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $124.59 | 2024 | |
| Sight Sciences, INC. | $123.64 | 2025 | Tearcare System |
| Lumenis, INC | $122.54 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $113.38 | 2019 | |
| Ocular Therapeutix, INC. | $91.56 | 2023 | Dextenza |
| Abbvie INC. | $49.89 | 2022 | |
| Alcon Research LLC | $19.63 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.44 | 2020 | |
| Optovue, INC. | $15.33 | 2019 | |
| Shire North American Group INC | $14.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lena Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.